Benutzer: Gast  Login
Titel:

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).

Dokumenttyp:
Article; Journal Article
Autor(en):
Tintelnot, Joseph; Goekkurt, Eray; Binder, Mascha; Thuss-Patience, Peter; Lorenzen, Sylvie; Knorrenschild, Jorge Riera; Kretzschmar, Albrecht; Ettrich, Thomas; Lindig, Udo; Jacobasch, Lutz; Pink, Daniel; Al-Batran, Salah-Eddin; Hinke, Axel; Hegewisch-Becker, Susanna; Nilsson, Sven; Bokemeyer, Carsten; Stein, Alexander
Abstract:
BACKGROUND: Esophagogastric adenocarcinoma (EGA) currently represents a main cause of cancer related death. Despite an intensified treatment for locally advanced or metastatic EGA with a doublet chemotherapy consisting of a platinum compound and a fluoropyrimidine in combination with trastuzumab for HER2-positive disease or in selected cases with docetaxel, survival remains poor. Recently, immune-oncology based strategies relevantly improved the treatment of different solid tumors and showed som...     »
Zeitschriftentitel:
BMC Cancer
Jahr:
2020
Band / Volume:
20
Heft / Issue:
1
Volltext / DOI:
doi:10.1186/s12885-020-06958-3
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/32487035
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX